Last reviewed · How we verify

NCT03361124

Oxytocin Dosing at Planned Cesarean Section and Anemia

Withdrawn Phase 4 Last updated 21 February 2019
What this trial tests

Phase 4 trial testing Oxytocin in Blood Loss Anemia. Withdrawn.

Timeline
1 March 2019
Primary endpoint
1 March 2020
1 March 2020

Quick facts

Lead sponsorMilton S. Hershey Medical Center
PhasePhase 4
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Start date1 March 2019
Primary completion1 March 2020
Estimated completion1 March 2020

Drugs / interventions tested

Conditions studied

Sponsor

Milton S. Hershey Medical Center

Who can join

18 and older, female only, with Blood Loss Anemia or Uterine Atony With Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patient's with planned cesarean sections will be randomized to receive either standard 20 mU in 1L as a bolus following delivery of the placenta or 20 mu in 1L following delivery of the placenta plus an additional 20 mU in 1L over 8 hours.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Oxytocin

Trials testing the same drug.

Other recruiting trials for Blood Loss Anemia

Currently open trials in the same condition.

Other Milton S. Hershey Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03361124.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing